TR200402696T4 - 1-(4-Hidroksifenil)2- (4-Hidroksi-4-fenilpiperidin-1-İl)-1- Propanolün mesilat tuzu trihidratının hazırlanması işlemi - Google Patents

1-(4-Hidroksifenil)2- (4-Hidroksi-4-fenilpiperidin-1-İl)-1- Propanolün mesilat tuzu trihidratının hazırlanması işlemi

Info

Publication number
TR200402696T4
TR200402696T4 TR2004/02696T TR200402696T TR200402696T4 TR 200402696 T4 TR200402696 T4 TR 200402696T4 TR 2004/02696 T TR2004/02696 T TR 2004/02696T TR 200402696 T TR200402696 T TR 200402696T TR 200402696 T4 TR200402696 T4 TR 200402696T4
Authority
TR
Turkey
Prior art keywords
phenylpiperidin
hydroxyphenyl
hydroxy
preparation
propanol
Prior art date
Application number
TR2004/02696T
Other languages
English (en)
Turkish (tr)
Inventor
Philip Rainville Joseph
Terry Gene Sinay Jr.
Walter Walinsky Stanley
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200402696T4 publication Critical patent/TR200402696T4/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
TR2004/02696T 2000-04-28 2001-04-24 1-(4-Hidroksifenil)2- (4-Hidroksi-4-fenilpiperidin-1-İl)-1- Propanolün mesilat tuzu trihidratının hazırlanması işlemi TR200402696T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
TR200402696T4 true TR200402696T4 (tr) 2004-11-22

Family

ID=22742684

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/02696T TR200402696T4 (tr) 2000-04-28 2001-04-24 1-(4-Hidroksifenil)2- (4-Hidroksi-4-fenilpiperidin-1-İl)-1- Propanolün mesilat tuzu trihidratının hazırlanması işlemi

Country Status (27)

Country Link
US (1) US6645986B2 (cg-RX-API-DMAC10.html)
EP (2) EP1151995B1 (cg-RX-API-DMAC10.html)
JP (2) JP3615496B2 (cg-RX-API-DMAC10.html)
KR (1) KR100442718B1 (cg-RX-API-DMAC10.html)
CN (2) CN1590373A (cg-RX-API-DMAC10.html)
AR (1) AR028376A1 (cg-RX-API-DMAC10.html)
AT (1) ATE277014T1 (cg-RX-API-DMAC10.html)
AU (1) AU781436B2 (cg-RX-API-DMAC10.html)
BR (1) BR0101630A (cg-RX-API-DMAC10.html)
CA (1) CA2345582C (cg-RX-API-DMAC10.html)
CZ (1) CZ20011471A3 (cg-RX-API-DMAC10.html)
DE (1) DE60105689T2 (cg-RX-API-DMAC10.html)
DK (1) DK1151995T3 (cg-RX-API-DMAC10.html)
ES (1) ES2227071T3 (cg-RX-API-DMAC10.html)
HK (1) HK1040246B (cg-RX-API-DMAC10.html)
HU (1) HUP0101723A3 (cg-RX-API-DMAC10.html)
ID (1) ID30006A (cg-RX-API-DMAC10.html)
IL (1) IL142705A0 (cg-RX-API-DMAC10.html)
IN (1) IN191027B (cg-RX-API-DMAC10.html)
PL (1) PL347298A1 (cg-RX-API-DMAC10.html)
PT (1) PT1151995E (cg-RX-API-DMAC10.html)
RU (1) RU2203888C2 (cg-RX-API-DMAC10.html)
SI (1) SI1151995T1 (cg-RX-API-DMAC10.html)
TR (1) TR200402696T4 (cg-RX-API-DMAC10.html)
TW (1) TW200505858A (cg-RX-API-DMAC10.html)
YU (1) YU27701A (cg-RX-API-DMAC10.html)
ZA (1) ZA200103320B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7299301A (en) * 2000-06-21 2002-01-02 Bioarray Solutions Ltd Multianalyte molecular analysis using application-specific random particle arrays
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US7754500B2 (en) 2003-11-21 2010-07-13 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
CA2606815C (en) 2005-05-02 2017-03-07 Anp Technologies, Inc. Polymer conjugate enhanced bioassays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
IL122649A (en) * 1995-08-11 2001-08-26 Pfizer (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
SI1151995T1 (en) 2004-12-31
BR0101630A (pt) 2001-12-04
HU0101723D0 (en) 2001-07-30
EP1151995A1 (en) 2001-11-07
CA2345582C (en) 2006-05-30
IL142705A0 (en) 2002-03-10
TW200505858A (en) 2005-02-16
JP2004196823A (ja) 2004-07-15
CN1210262C (zh) 2005-07-13
DE60105689D1 (de) 2004-10-28
YU27701A (sh) 2003-04-30
US6645986B2 (en) 2003-11-11
PL347298A1 (en) 2001-11-05
HK1040246B (zh) 2005-10-28
EP1151995B1 (en) 2004-09-22
AU3889601A (en) 2001-11-01
PT1151995E (pt) 2004-11-30
CZ20011471A3 (cs) 2002-02-13
JP2001354651A (ja) 2001-12-25
KR100442718B1 (ko) 2004-08-02
CN1590373A (zh) 2005-03-09
ZA200103320B (en) 2002-10-24
IN191027B (cg-RX-API-DMAC10.html) 2003-09-13
CN1321638A (zh) 2001-11-14
HK1040246A1 (en) 2002-05-31
ATE277014T1 (de) 2004-10-15
ES2227071T3 (es) 2005-04-01
EP1477479A1 (en) 2004-11-17
AR028376A1 (es) 2003-05-07
CA2345582A1 (en) 2001-10-28
US20020016465A1 (en) 2002-02-07
DE60105689T2 (de) 2005-11-10
ID30006A (id) 2001-11-01
DK1151995T3 (da) 2004-12-13
RU2203888C2 (ru) 2003-05-10
KR20010098960A (ko) 2001-11-08
HUP0101723A3 (en) 2003-03-28
HUP0101723A2 (hu) 2002-02-28
JP3615496B2 (ja) 2005-02-02
AU781436B2 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
BRPI0416143A (pt) sais farmaceuticamente aceitáveis de compostos de quinolinona tendo propriedades farmacêuticas aperfeiçoadas
LU93229I2 (fr) "pitolisant et ses sels pharmaceutiquement acceptables, tel que chlorhydrate"
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
DE69530690D1 (de) Benzoheterocyclische derivate verwendbar als vasopressin- oder oxytocin-modulatoren
GB9801690D0 (en) Therapeutic agents
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
PT1003725E (pt) Fungicidas de fluoropirazoldifenilamidas
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
EA200400140A1 (ru) Пероральные противодиабетические агенты
ATE384049T1 (de) Therapeutische heterocyclen als bradykinin b2 rezeptor antagonisten
BR9813719A (pt) Agentes terapêuticos
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
PE20050440A1 (es) Derivados de n-heterociclo sustituidos para modificar la recaptacion de monoaminas
BR0311192A (pt) Compostos amidoacetonitrila
NO20043377L (no) R-(-)-1-[2-(7-klorbenzo[b]tiofen-3-yl-metoksy)-2-(2,4-diklorfenyl)-etyl]-1H-imidazol
CA2432138A1 (en) New process for the preparation of eletriptan
NO20004545L (no) FremgangsmÕte for fremstilling av (R)-<alfa>-(2,3- dimetoksyfenyl)-1-[2-(4-fluorofenyl)etyl]-4-piperidinmetanol
TW200505858A (en) Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol
SE9704770D0 (sv) New use
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung